Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl cis-trans isomerase FKBP8 (FKBP8) is a member of the immunophilin protein family, encoded by the FKBP8 gene in humans. While structurally related to other FKBP proteins, FKBP8 is unusual in that it lacks classic peptidyl-prolyl isomerase (PPIase) activity unless activated by calcium-bound calmodulin, acting instead largely as a chaperone. FKBP8 forms complexes with BCL2 protein and calmodulin, helping regulate mitochondrial localization and phosphorylation status of BCL2, thereby modulating apoptosis in cells. FKBP8 is also implicated in cellular protein folding, trafficking, and immune regulation, with roles in neuronal processes and memory. Disease associations include cancer, viral infections (such as hepatitis C and influenza A), and certain germinomas[1][2][3][6]. FKBP8 is known to interact with the immunosuppressive drug tacrolimus (FK506), though its distinct mechanism limits classic immunosuppressive activity observed in other FKBPs[3][6].
Inhibition of protein interactions via FK506-binding, Potential modulation of apoptosis via BCL2 pathway chaperoning
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP8 (FKBP8).